Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons

Abstract

Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD+ levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD+) levels to prevent dementia. We tested if the administration of the precursor of NAD+, nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD+ levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p < 0.001), glutamate (p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p < 0.001) and decreased levels of N-acetyl aspartate (p = 0.002) and glutathione (p < 0.001). There was a significant decrease in hippocampal CA1 neuronal volume (p < 0.001) and neuronal number (p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD+ levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD+, activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats.

Securidaca inappendiculata Polyphenol Rich Extract Counteracts Cognitive Deficits, Neuropathy, Neuroinflammation and Oxidative Stress in Diabetic Encephalopathic Rats via p38 MAPK/Nrf2/HO-1 Pathways

“…Hyperglycemia plays a crucial role in neuronal damage through the instigation of oxidative stress sensitive pathways leading to neuronal apoptosis and damage. In addition, diabetic alterations has been largely reported to influence learning and memory function ( Thakur et al, 2016 ; Chandrasekaran et al, 2020 ; Shin et al, 2021 ). As such, maintaining normal glycaemic control is paramount in the treatment of diabetes so as to prevent any diabetic associated complication including DE.…”

Silver Nanoparticles Conjugate Attenuates Highly Active Antiretroviral Therapy-Induced Hippocampal Nissl Substance and Cognitive Deficits in Diabetic Rats

“…Its long-term effects on the brain can manifest at physiological and structural levels [5]. In diabetic subjects and experimental rats, cognitive dysfunction has been reported in various literature [6][7][8].…”

Decreased Urinary Levels of SIRT1 as Non-Invasive Biomarker of Early Renal Damage in Hypertension

“…It is worthy of note that the implication and importance of SIRT1 in kidney-related diseases, such as diabetic nephropathy [ 26 , 32 , 33 , 34 ], acute and chronic kidney disease [ 19 , 35 , 36 ] or lupus nephritis [ 27 , 37 ] can be explained by its involvement in numerous pathways regulation. SIRT1 regulates the TGFβ/Smad and ERK1/2 pathways, also activates metalloproteinases and FOXO1 proteins and controls the NF-kB pathway [ 24 , 37 , 38 ].…”